title: [Influence of intensive hypolipidemic therapy on blood concentration of lipoprotein-associated phospholipase A2 in patients with ischemic heart disease].
abstract: OBJECTIVE
  To assess the impact of combined treatment with simvastatin and ezetimibe or treatment with simvastatin only on lipoprotein-associated phospholipase A2 in patients with ischemic heart disease.
  
  
  METHODS
  One hundred patients with angiographically documented coronary atherosclerosis took part in the investigation. Lp-PLA2 mass and cholesterol fractions were determined at baseline and after 6 months of treatment. Lp-PLA2 mass was determined by enzyme immunoassay method, using two highly specific monoclonal antibodies.
  
  
  RESULTS
  Combined treatment with ezetimibe and simvastatin led to significantly greater declines in Lp-PLA2 and cholesterol fractions compared with treatment only with simvastatin: Lp-PLA2 decreased by 46 vs 38%, total cholesterol by 35 vs 28%, LDL cholesterol by 50 vs 40%, respectively (p<0.05). Combination therapy with ezetimibe and simvastatin 20 and 40mg/day proved to be as effective as monotherapy with simvastatin 80 mg/day on the effect on Lp-PLA2 mass and cholesterol fractions (p<0.05). Lp-PLA2 correlated positively with total cholesterol (r=0.28) and LDL-C (r=0.33).
  
  
  CONCLUSIONS
  Combined treatment led to greater reduction of total cholesterol and LDL-C, as well as significantly reduced level of Lp-PLA2 mass. The latter can be considered as target for suppression of inflammation and achievement of stabilization of atherosclerotic plaque.
authors.affiliation: Institute of Clinical Cardiology of Russian Cardiology Scientific and Production Center, ul. Tretiya Cherepkovskaya 15a, 121552 Moscow, Russia.
authors.forename: S V
authors.initials: SV
authors.lastname: Miklishanskaia
authors.forename: T N
authors.initials: TN
authors.lastname: Vlasik
authors.forename: G I
authors.initials: GI
authors.lastname: Kheĭmets
authors.forename: E I
authors.initials: EI
authors.lastname: Kaznacheeva
authors.forename: A A
authors.initials: AA
authors.lastname: Liakishev
authors.forename: V V
authors.initials: VV
authors.lastname: Kukharchuk
mesh_terms: D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000097:blood*; D000328:Adult; D000368:Aged; D000924:Anticholesteremic Agents / Q000008:administration & dosage; D001384:Azetidines / Q000008:administration & dosage*; D002784:Cholesterol / Q000097:blood*; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy; D016903:Drug Monitoring; D004359:Drug Therapy, Combination; D000069438:Ezetimibe; D005260:Female; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D012720:Severity of Illness Index; D019821:Simvastatin / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D001384:Azetidines; D002784:Cholesterol; D019821:Simvastatin; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase; D000069438:Ezetimibe